Nanjing Legend Biotech Co., Ltd.

Schering Corporation

Merck Sharp + Dohme Corp.

Legend Biotech USA Inc.

Legend Biotech Ireland Limited

Chuan-Chu Chou

Shu Wu

Shuai Yang

Yafeng Zhang

Kevin W Moore

Jimmy C Tan

Di-Hwei Hsu

Ying Liu

Alice Suk-Yue Ho

J Fernando Bazan

Loretta A Bober

Lee Sullivan

Nicholas J Murgolo

William T Windsor

Paul J Zavodny

Stephen Tindall

Mary E Petro

Jon E Silver

Leonard G Presta

Lin Wang

John S Abrams

Wang Zhang

Chung-Her Jenh

Qiuchuan Zhuang

Pingyan Wang

Lei Yang

Xiaohu Fan

Liusong Yin

Jiaying Hao

Feng Lin

Zhongdao Li

Bazan Fernando J

Zhenyu Liu

Fangliang Zhang

Xinpo Jiang

Qi Pan

Fei Sun

The present application provides an antibody, such as a monoclonal antibody (mAb), or an antigen binding fragment thereof, that specifically recognizes PD-L1. Also provided are pharmaceutical compositions, or methods of making and using the antibody or antigen binding fragment thereof.

Antibodies and variants thereof against PD-L1

The present application provides anti-LAG-3 constructs comprising a single-domain antibody (sdAb) that specifically recognizes LAG-3. Also provided are methods of making and using these constructs.

Single-domain antibodies against LAG-3 and uses thereof

Provided are constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes TIGIT. Also provided are methods of making and using these constructs.

Single-domain antibodies and variants thereof against TIGIT

Provided are constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes PD-1. Also provided are methods of making and using these constructs.

Single-domain antibodies and variants thereof against PD-1

The present application provides an antibody, such as a monoclonal antibody (mAb), or an antigen binding fragment thereof, that specifically recognizes TIGIT. Also provided are pharmaceutical compositions, or methods of making and using the antibody or antigen-binding fragment thereof.

Antibodies and variants thereof against TIGIT

The present application provides constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes PD-L1. Also provided are methods of making and using these constructs.

Single-domain antibodies and variants thereof against PD-L1

Novel antibodies, such as single domain antibodies (sdAbs), or antigen-binding fragments thereof that specifically bind a transferrin are described. Compositions, methods and systems for increasing the half-life of a target protein in a serum using an antibody or fragment thereof against a transferrin are also described.

Compositions and methods using a single-domain antibody binding transferrin and protein A for increasing protein half-life in serum

The present application provides constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Also provided are methods of making and using these constructs.

Single-domain antibodies and variants thereof against CTLA-4

Disclosed herein are multispecific, such as bispecific, antigen binding proteins comprising a first antigen binding domain comprising a heavy chain variable domain and a light chain variable domain, and a second antigen binding domain comprising a single-domain antibody. Pharmaceutical compositions comprising the multispecific antigen binding proteins, kits and methods of use thereof are further provided.

Multispecific antigen binding proteins and methods of use thereof

The present application provides single-domain antibodies, and chimeric antigen receptors comprising one or more antigen binding domains each comprising a single-domain antibody. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

Chimeric antigen receptors based on single domain antibodies and methods of use thereof

The present invention provides, in part, MCP1-Ig fusion polypeptides exhibiting surprisingly beneficial properties as well as methods for treating various diseases (e.g., inflammatory diseases) by administering any of such fusions.

MCP1-Ig fusion variants

The present invention provides polypeptides including MCP1 fused, optionally, by a linker, to an immunoglobulin. Methods for using the polypeptides to treat medical disorders are also covered.

Method for treating atherosclerosis by administering human MCP1 fusions

Methods for treating rheumatoid arthritis and multiple sclerosis using MCP1 fusions

MCP1 fusions

A monoclonal antibody is provided which specifically binds to human interleukin-5. Also provided are a hybridoma which produces the monoclonal antibody; complementary DNAs which encode the heavy and light chain variable regions of the monoclonal antibody and CDRs therefrom; humanized monoclonal antibodies; and pharmaceutical compositions comprising the monoclonal antibody or anti-idiotypic antibodies directed against it, humanized monoclonal antibodies, binding fragments, binding compositions or single-chain binding proteins derived from the antibody and a physiologically acceptable carrier.

Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5

Growing community of inventors

Westfield, NJ, United States of America

Chuan-Chu Chou